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Hypoxia-Inducible Factor (HIF)-1† is a dimeric protein complex that plays an integral role
in the body’s response to low oxygen concentrations, or hypoxia. HIF-1 is among the pri-
mary genes involved in the homeostatic process, which can increase vascularization in
hypoxic areas such as localized ischemia and tumors. It is a transcription factor for
dozens of target genes; HIF-1 is also essential for immunological responses and is a cru-
cial physiological regulator of homeostasis, vascularization, and anaerobic metabolism.
Furthermore, HIF-1 is increasingly studied because of its perceived therapeutic potential.
As it causes angiogenesis, enhancement of this gene within ischemic patients could pro-
mote the vessel proliferation needed for oxygenation. In contrast, as HIF-1 allows for sur-
vival and proliferation of cancerous cells due to its angiogenic properties, inhibition
potentially could prevent the spread of cancer. With a growing understanding of the HIF-1
pathway, the inhibition and stimulation of its transcriptional activity via small molecules is
now an attractive goal. Gene therapy to achieve both vessel proliferation and tumor re-
gression has been demonstrated in animal studies but requires significant improvement
and modification before becoming commercially available. This review focuses on the po-
tential of the HIF-1 pathway in therapeutic intervention for the treatment of diseases such
as cancer and ischemia.
OXYGEN METABOLISM
IN MAMMALS
Oxygen is required by the cells of most
organisms to produce adequate amounts of
ATPnecessary for metabolic activities. Hy-
poxia, or oxygen deprivation, occurs within
human tissues and cells due to a variety of
conditions, including disorders of the heart
and lungs, anemia, and circulatory prob-
lems. Depending on the severity, perma-
nent damage to tissues and cells may occur
[1].
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portant and beneficial role in human physi-
ology and development. It is integral for
proper embryonic development. Although
the exact mechanisms are unknown, oxygen
tension is related to closure of the neural
tube, mediation of apoptosis, and proper
morphological development during gesta-
tion. Such findings indicate that in addition
to genetic cues, environmental conditions
such as hypoxia serve as signals in embry-
onic development [2,3,4].
Many organisms have evolved adaptive
mechanisms for hypoxic conditions. Chang-
ing oxygen levels can result in activation or
repression of certain homeostatic regulatory
genes, allowing for the survival of tissues
and cells despite fluctuating environmental
conditions. Genes such as HIF-1, whose ac-
tivation is prompted by hypoxic conditions,
can interact with enzymes and other tran-
scription factors in order to control vascu-
larization and tissue growth. While
microenvironments surrounding cancerous
tumors are extremely hypoxic, proliferation
of such masses often is made possible by
HIF-1 activation, which leads to increased
angiogenesis and, thus, an increased oxygen
supply to the area [5,6].
Given its prominent function, manipu-
lation of HIF-1 activity within areas of is-
chemia and tumor masses has become a
focus in the effort to develop noninvasive,
pharmaceutical treatment options for cancer
and heart disease patients.Although no such
human protein has been successfully regu-
lated by scientific means, control of HIF-1
activity is increasingly feasible as details of
its structure, function, and genetic pathway
are elucidated.
HIF-1 DOMAIN STRUCTURE
HIF-1 is a heterodimeric transcription
factor consisting of a constitutively ex-
pressed β-subunit and an oxygen-regulated
α-subunit.The HIF-1α and HIF-1β proteins
both contain basic helix-loop-helix motifs
that bind DNA and cause subunit dimeriza-
tion [7,8,9]. Both subunits also have a Per-
ARNT-Sim (PAS) domain, with similar
functions. In the α-subunit, there is an oxy-
gen-dependent degradation (ODD) domain,
which is hydroxylated by proline-hydroxy-
lase-2 (PHD-2), rendering the α-subunit vul-
nerable to proteasomal degradation under
normoxic cellular conditions [10].The struc-
ture of HIF-1α and HIF-1β is depicted in
Figure 1.
The HIF-1α subunit also contains two
transactivation domains (TAD), which regu-
late HIF-1 target genes. CREB binding pro-
tein (CBP) and p300, two transcriptional
co-activators of HIF-1, interact with the car-
boxy-terminal transactivation domain (C-
TAD) of HIF-1α.
Both activators are essential for HIF-
1 transcription and are therefore targets in
the effort to regulate HIF-1 expression; in-
hibition of HIF-1α C-TAD interactions by
proline hydroxylation inhibits HIF-1 gene
expression, preventing normal transcrip-
tion and translation [11]. HIF-1β contains
only one such analogous region, which is
unnecessary for HIF-1 complex function
[7,10,12]. Recent reports show that HIF-
1β is identical to the previously discov-
ered vertebrate protein, aryl hydrocarbon
receptor nuclear translocator (ARNT)
[12].
Figure 1. The structure of the HIF-1α and
HIF-1β genes. These genes contain a basic
helix-loop-helix (bHLH) motif and PER-
ARNT-SIM (PAS) domain, both of which aid
in dimerization and the binding of the sub-
units to DNA. The carboxy-terminal transac-
tivation domains of these genes serve as
regulatory and transactivation regions. Tran-
scriptional activators CBP and p300 bind to
the TAD-C region of the HIF-1α gene. Also
depicted on the diagram of HIF-1α gene is
the inhibitory domain, an important regula-
tory region.
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HIF-1 REGULATES OXYGEN
HOMEOSTASIS
HIF-1 is a major regulator of oxygen
homeostasis within cells. As a transcription
factor, it affects and regulates the expression
of dozens of genes involved in maintaining
homeostasis as oxygen concentrations
change [13]. HIF-1 further mediates cellular
responses to hypoxia by regulating glucose
uptake and anaerobic respiration in oxygen-
depleted environments [5,2].
Transcriptional Regulation Controls
Angiogenesis in Hypoxia
One important HIF-1 function is to
promote angiogenesis; HIF-1 directs mi-
gration of mature endothelial cells toward
a hypoxic environment [2,5]. This is done
via HIF-1 regulation of vascular endothe-
lial growth factor (VEGF) transcription.
VEGF is a major regulator of angiogene-
sis, which promotes endothelial cell migra-
tion toward a hypoxic area. During
hypoxia, HIF-1 binds the regulatory region
of the VEGF gene, inducing its transcrip-
tion and initiating its expression
[12,15,16]. Such endothelial cells ulti-
mately help to form new blood vessels,
supplying the given area with oxygenated
blood [14].
HIF-1 Regulates Shift to
Anaerobic Metabolism
HIF-1 also can regulate anaerobic
metabolism. When oxygen is available,
most cells produce ATP via oxidative
phosphorylation. However, in hypoxic en-
vironments, there is a shift to anaerobic
metabolism for cellular energy produc-
tion. HIF-1 is among the principal genes
to coordinate this shift, by inducing a va-
riety of glycolytic enzymes and glucose
transporters such as aldolase A and pyru-
vate kinase M, which help cells effi-
ciently produce energy in hypoxic
environments [5,16]. In addition to in-
creasing the expression of these enzymes,
HIF-1 decreases mitochondrial oxygen
consumption by activating pyruvate dehy-
drogenase kinase I and halting the citric
acid cycle [17].
CANCER, INFLAMMATION,
AND HYPOXIA
Environmentssurroundingmetastasizing
tumor masses are often hypoxic. HIF-1 is a
crucialproteininsuchmasses;itenablestumor
progressionbyinducingalternativemetabolic
pathways within cancer cells, as discussed
above in the context of physiologic hypoxia.
Tumor Proliferation
Due to its role in hypoxia, HIF-1 plays
a critical part in tumor proliferation [18].As
a tumor develops and grows, a hypoxic en-
vironment is created because of the extreme
energy demands of the numerous, rapidly di-
viding cells. Angiogenesis is often induced
by such cellular masses to meet the needs for
increased oxygen, energy, and blood sup-
plies [5,16]. Concurrently, HIF-1 contributes
to the shift to anaerobic metabolism. The
importance of this transcription factor in
tumor cell survival is reflected in the finding
that the levels of HIF-1α in glioma tumor
cells increase proportionally with the grade
of the tumor [19].
The mechanisms of HIF-1 mediated
tumor survival have been partially revealed
by the work of Semenza et al. onVHL-lack-
ing renal carcinoma cells. HIF-1 was found
to decrease oxygen consumption in these
cells by inhibiting C-MYC, a transcription
factor that regulates mitochondrial mass and
oxygen consumption and is known to be
down-regulated in a variety of human can-
cers. Semenza et al. report that HIF-1 de-
creases levels of C-MYC by increasing the
transcription of MXI1, a repressor of C-
MYC, and by increasing the rates of proteo-
some degradation of the C-MYC protein.
The decreased levels of C-MYC in these
cancer cells were found ultimately to lead to
increased glycolysis and decreased mito-
chondrial respiration, crucial characteristics
of cancer cells that survive and proliferate in
the hypoxic conditions of the tumor micro-
environment [20].
Overexpression of HIF-1 Causes
Apoptosis
A multitude of studies currently are
being conducted on the role of HIF-1 in hy-poxia-induced apoptosis of various cell
types. For example, Krick et al. recently re-
ported that overexpression of HIF-1 in alve-
olar epithelial cells resulted in increased
apoptosis [21].Although the exact pathways
and mechanisms involved in this process re-
main unclear, data suggest that in hypoxic
conditions the tumor suppressor p53 is acti-
vated. Via interaction with the HIF-1 pro-
tein, p53 is stabilized and begins to activate
genes such as p21, which, in turn, cause cell
death [5,21].
HIF-1 Supports Inflammatory
Responses and Hypoxic Recovery
In addition to its other roles in adapta-
tion to hypoxia, HIF-1 has been shown to
play a role in inflammation. Cramer and
coworkers demonstrated that HIF-1 is nec-
essary for metabolism within myeloid cells
[22]. Overexpression of HIF-1 in vivo re-
sulted in increased localized inflammation,
while loss of the HIF-1 gene decreased the
ability of myeloid cells to aggregate, mi-
grate, and promote bactericidal responses.
This dependence of myeloid cells on HIF-1
may be related to their reliance on anaerobic
respiration as a means of energy production.
Myeloid cells lacking this gene are unable
to efficiently produce ATP, effectively mi-
grate to injured tissues, or destroy foreign
invaders [22]. In addition, HIF-1α expres-
sion plays a role in the differentiation of
myeloid cells into monocytes and
macrophages [23].
In contrast, HIF-1 can function to pre-
vent tissue and cardiac damage caused by is-
chemia, which may result in a variety of
long-term cardiac problems. Overexpression
of HIF-1 in such tissues can cause angiogen-
esisandthusincreaseoxygenationofthearea
[24,25]. This serves as the basis for the cur-
Figure 2. The hypoxia-inducible factor (HIF)-1 pathway. The HIF-1α gene is transcribed in the
nucleus with the help of specificity protein (Sp) 1, P300, and HIF-1β. Once translated in the cy-
toplasm, the HIF-1α protein can either become hydroxylated and ubiquinated, in which case
it will be degraded by proteasomes (under normal oxygen conditions). In the setting of hypoxia,
it can re-enter the nucleus and form a transcription complex with the HIF-1β subunit. If success-
fully stabilized with the latter subunit, the final complex ultimately will function to regulate target
genes such as vascular endothelial growth factor and cathepsin D. Possible therapeutic in-
tervention points are: the hydroxylation that leads to degradation of HIF-1α, the binding of HIF-
1α to its coactivators, and the modulation of HIF-1α activity. Additionally, gene therapy
approaches have been used to induce the overexpression of HIF or the disruption of the HIF
pathway with antisense oligonucleotides. Abbreviations: PHD: proline-hydroxylase domain
containing molecules; Ub: ubiquitin; VHL: von Hippel-Lindau protein.
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rent efforts to find pharmaceutical and other
non-invasive treatments for ischemia and re-
lated diseases.
ACTIVATION AND SUPPRESSION
PATHWAYS
Normoxia Causes Degradation;
Hypoxia Allows Activation
Under normoxic conditions, HIF-1α is
degraded by proteasomes. The HIF-1α sub-
unit is “marked” for such degradation by
proline-hydroxylase-2 (PHD-2) and by von-
Hippel-Lindau (VHL)-ubiquitin ligase com-
plexes. Therefore, HIF-1 does not function
in the presence of sufficient oxygen [10,26].
Also contributing to HIF-1 inactivation in
normoxic conditions is Factor Inhibiting
HIF-1 (FIH) protein, which hydroxylates
HIF-1, preventing interaction of this subunit
with the co-activators p300 and CBP. Ex-
pression and stabilization of the HIF-1 com-
plex is regulated via feedback inhibition, as
PHD-2 itself is activated by HIF-1 [12].
However, in hypoxic conditions, HIF-1
protein is stable and active as hydroxylases,
VHLproteins, and FIH are all inhibited by a
lackofoxygen.ThenHIF-1isabletointeract
with its co-activators and can dimerize with
its constitutively expressed β-subunit. Once
stabilized, the HIF-1 protein can bind to the
regulatory regions of its target genes, induc-
ing their expression [7,10,27] (Figure 2).
Oxygen-Independent Stimuli
A variety of HIF-1 stimuli function in-
dependently of oxygen concentration.These
stimuli are primarily proteins, which regu-
late HIF-1 translation, contrasting sharply
with the hypoxic stimuli of this gene, which
act upon the already expressed α-subunit.
Protein kinase C (PKC) increases the rate of
HIF-1α transcription of and functions in
conjunction with the phosphatidylinositol 3-
kinase (PI3K) pathway, which also enhances
HIF-1α translation. The PKC pathway acti-
vates expression of the S6 ribosomal pro-
tein, which specifically recognizes mRNA
transcripts such as HIF-1α. Via phosphory-
lation of the S6 protein in normoxic condi-
tions, the rates of HIF-1α mRNAtranslation
can be greatly increased, effectively coun-
tering the effects of the proteasome degra-
dation of this subunit and increasing levels
of the HIF-1 complex within the cell. The
PI3K pathway has been identified as the pri-
mary means by which various mediators,
such as lipopolysaccharides, affect activa-
tion of HIF-1α in vascular smooth muscle
cells and macrophages [12,27].
THERAPEUTIC TARGETS IN THE
HIF-1 PATHWAY: ISCHEMIA
Overexpression
In the case of ischemia treatments, HIF-
1α upregulation may stimulate angiogenesis
and increase blood flow. Many genes in-
volved in angiogenesis, such as VEGF, ma-
trix metalloproteinase 2 (MMP2), cathepsin
D (CATHD), and keratin (KRT), are targets
of the HIF-1 transcription complex. It is be-
lieved increased HIF-1 levels lead to propor-
tional increases in these proteins [12,28]. In
several recent studies, mice injected with
HIF-1α DNA lacking an ODDD displayed
increased blood supply to wounded or is-
chemic areas, suggesting increases in HIF-
1α levels can aid in supply of blood,
oxygen, and nutrients to areas of focal is-
chemia [29,30].
Introduction of a constitutively stable
HIF-1α hybrid to rat cardiomyocytes re-
sulted in decreased ischemic damage. This
hybrid consisted of the DNA-binding and
dimerization domains from HIF-1α and the
transactivation domain of HSV VP16 pro-
tein [31]. HIF-1α overexpression in mouse
myocardial infarction models reduces infarct
size, thereby preserving cardiac function
[32]. Increasing HIF-1 expression may
prove to be a successful pharmaceutical
treatment for ischemic patients on whom
surgery cannot be performed.
Direct HIF-1 Modifications
Direct phosphorylation of the HIF-1α
subunit itself can increase HIF-1 activity,
presumably by impeding proteasome/VHL
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about phosphorylation of HIF-1α, p42/p44
mitogen activated protein kinases phospho-
rylate this protein in vitro. In vivo, such
phosphorylation is necessary for HIF-1
function.Activation of the p42/p44 pathway
results in increased levels of HIF-1α tran-
scription. This phosphorylation may be an
optimal step in the HIF-1 pathway to induce
overexpression [33].
The HIF-1 hydroxylases consist of sev-
eral related molecules, including Factor In-
hibiting HIF (FIH) and Prolyl Hydroxylase
Domain (PHD) proteins. As VHL mediates
proteasome degradation of hydroxylated
HIF-1α, the levels of HIF-1α can be in-
creased by silencing HIF-1alpha-prolyl-4
hydroxylase-2 (PHD2). Inhibition of PHD2
via siRNA also results in a decrease in the
cardiac infarction size in mice. These path-
ways may be amenable to pharmacological
approaches [34].
Small Molecule Inhibitors
Several small molecules, such as di-
methyloxalylglycine, a prolyl hydroxylase
inhibitor, activate HIF-1. Hydroxylase activ-
ity can be rescued by mutating specific re-
gions or by adding cobalt ions to the cell,
which presumably compete for iron binding
sites [35]. Some hydroxylases in the prolyl
family can be selectively inhibited by adri-
amycin in vitro [36]. Cobalt (II) and Nickel
(II) ions in cells increase HIF-1 activity, pre-
sumably as such ions displace the iron from
the active sites of 2OG hydroxylases.
Small molecule therapy may be useful
not only in HIF-1 suppression, but also in its
activation for the treatment of ischemic dis-
eases [7]. Hormones such as angiotensin II
and platelet-derived growth factor stimulate
the HIF pathway by increasing HIF-1α pro-
tein levels via production of reactive oxygen
species (ROS) within the cell.Although the
exact mechanism is unclear, it appears to be
entirely distinct from the hypoxia pathways.
Thrombin and other growth factors increase
angiogenesis via HIF-1α protein agonist
mechanisms [14,33]. Insulin likewise acti-
vates HIF-1α by activating multiple protein
kinases necessary for expression and func-
tion [37].
In another study on HIF-1 activation,
homozygous deletion of the p53 gene led to
HIF-1 activation [38]. Therefore, p53, re-
sponsible for promoting ubiquitination of
HIF-1α, may be another possible target.
Gene therapy eventually may be used to
increase HIF-1 levels and relieve complica-
tions of ischemia. For example, delivery of
a stabilized, recombinant form of HIF-1α
via adeno-associated virus (AAV) in order
to overexpress HIF-1 in skeletal muscle re-
sulted in significantly increased capillary
numbers [38,39]. While gene therapy ap-
proaches aimed at the process and effects of
angiogenesis continue to be developed and
studied, higher levels of success in preclini-
cal trials currently are being sought before
clinical applications are pursued.Among the
most prominent of the remaining obstacles
in gene therapy is the mode of delivery [38].
The search for the most efficient delivery
vector continues.
THERAPEUTIC TARGETS IN THE
HIF-1 PATHWAY: CANCER
With a clearer understanding of the
HIF-1 pathway, efforts are directed at ma-
nipulation of this complex genetic process
in order to ultimately increase or decrease
cellular HIF-1 levels. Although a human
transcription factor has yet to be success-
fully controlled through external manipula-
tion, such a goal remains attractive as it may
lead to non-invasive treatment methods for
diseases such as cancer and ischemia. Opti-
mal points in the HIF-1 pathway for such
therapeutic intervention are currently under
investigation.
The nature of cancer growth and metas-
tasis provides multiple phases at which ther-
apeutic intervention is possible. As HIF-1
has been found to regulate the shift within
the tumor cells to anaerobic metabolism and
to activate VEGF and angiogenesis, down-
regulation of the HIF-1 complex may sup-
press cancer progression. Among the
methods considered for HIF-1 downregula-
tion is the activation of hydroxylases, which
target the HIF-1 complex for eventual degra-
dation. Such hydroxylases are members ofZiello: HIF and therapeutic intervention 57
the 2-oxoglutarate (2OG)-dependent oxyge-
nase superfamily and require a ferrous ion
at the active site. Although the exact mech-
anism remains unknown, HIF-1α degrada-
tion is increased by treating cells with iron
and ascorbate, which most likely decrease
levels of HIF-1 protein and of HIF-target
genes by activating the hydroxylases [40].
Specific Therapeutic Targets: Proteins
HIF-1α binding to its co-activators has
also been a target for HIF-1 inhibition. The
CAD of HIF-1 must bind to the calponin ho-
mology 1 (CH1) domains of the co-activa-
tors CBP and p300 proteins to initiate
transcription [41,42,43]. When excess HIF-
1α-CAD polypeptides are transfected into
cells, the expression of hypoxia-inducible
reporters decreases [41,42]. These peptides
compete with HIF-1α for the CPB site, dis-
rupting the interaction, which is crucial for
downstream effects.
Stephen et al. have shown that
p300/CBP interaction with HIF-1α can be
prevented via stimulation of the CITED4
protein. CITED4 is a transcription factor
that binds to the CH1 domain of the
p300/CBP co-activators, thus competing
with co-activators for HIF-1α. In this study,
it was demonstrated that HIF-1α levels de-
crease with stimulation of CITED4 expres-
sion and tumor cells are capable of
decreasing the levels of CITED4, leading to
an increase in the amount of HIF-1α [33].
Alteration of specific HIF-1α amino
acid residue oxidation-reduction status can
suppress HIF-1 expression. Pleurotin and
PX-12 inhibit thioredoxin-1, which reduces
a residue in the C-TAD of HIF-1α, in turn
increasing the effectiveness of HIF-1 as a
transcription factor. Such inhibitors simulta-
neously decrease levels of VEGF within the
cell, as well as angiogenesis in tumors by a
mechanism unrelated to HIF-1 inhibition
[28]. The underlying mechanisms of these
effects remain unclear [44].
Specific Therapeutic Targets: Small
Molecules/RNA
Several small molecule inhibitors of
HIF-1 activity have been identified and are
currently being studied. Topotecan, a topoi-
somerase inhibitor, decreases cellular accu-
mulation of HIF-1α [31]; it may alter the
ribosome entry site on the HIF-1α mRNA
molecule, preventing translation [44,45].
103D5R is another small molecule that re-
cently has been found to have HIF-1α in-
hibiting properties. The molecular
mechanisms and pathways behind the re-
pression of HIF-1α by 103D5R are also un-
known, but it may have an action similar to
topotecan [42]. However, only in vitro stud-
ies of 103D5R have as yet been completed.
HIF-1-HIF-1α inhibition via gene ther-
apy has been investigated using both siRNA
and antisense RNA in various cell types.
Jensen et al. transfected glioma cells with
HIF-1α siRNA, which decreased cell
growth both in vivo and in vitro [46]. Similar
results were obtained by Sun et al.; plasmid
delivery of antisense HIF-1α led to de-
creased microvessel densities in EL-4 tu-
mors in mice [47]. Chang et al. recently
demonstrated that transfection of BxPc-3
cells with antisense HIF-1α results in de-
creased progression and metastasis of pan-
creatic cancer [48]. Although such results
have yet to be replicated in humans, they
have significant implications for the future
of cancer treatment. While less studied, the
VHL protein, which marks HIF-1α for
degradation, is another potential therapeutic
target. The VHL tumor suppressor gene be-
comes inactivated in many types of carcino-
mas, which causes increased HIF-1α levels
and allows for survival in hypoxia. As the
promoter regions inVHLin which transcrip-
tion factors bind now have been identified,
silencing may one day be possible [49].
CONCLUSIONS
As more is learned about functions, tar-
get genes, and activation pathways of HIF-
1, novel treatments of diseases such as
cancer and ischemia can be developed. De-
spite limited success in mouse ischemic
models and human clinical trials, significant
advances in manipulating HIF-1 expression
continue to be made [39]. Such results fur-
ther stress the need to target the HIF-1 path-Ziello: HIF and therapeutic intervention 58
waydirectly,asopposedtomerelyitseffects,
to truly develop efficient pharmaceutical
therapies. In this respect, advances in gene
therapy may allow for a greater ability to di-
rectly influence intracellular HIF-1 levels.
In the search to find a non-invasive
treatment for ischemia, it appears inhibition
of 2OG hydroxylases via small molecule
therapy is the most promising way to stimu-
late HIF-1 activity, assuming that selective
suppression of such hydroxylases ultimately
can be achieved. Selective inhibition of col-
lagen prolyl hydroxylases [7,12] and in clin-
ical trials of a 2OG-related enzyme,
cyclooxygenase II, have been successful
[50]. Suppression of HIF-1 in the treatment
of cancer is also a focus, as the significant
role of this transcription complex in tumor
progression is now recognized [15,16,19].
TheentirespectrumofHIF-1functionis
not yet understood. Accordingly, regulation
of transcription factor activation in humans
has not yet been achieved. That the various
HIF-1αhydroxylasesaffectandregulatelev-
elsofthistranscriptionfactordifferentlyonly
recently was described. Much remains to
learn about the selectivity and properties of
factors influencing the HIF-1 pathway [51].
Although current efforts to manipulate the
HIF-1 pathway have been principally cen-
teredontheneedfortreatmentsofcancerand
ischemia, it has been suggested that HIF-1α
may play a role in the onset of pulmonary fi-
brosis [52]. As the molecular mechanisms
leadingtotheonsetofthisdiseaseremainun-
known, HIF-1α inactivation in respiratory
cellsmaybeafruitfullineofinquiry.Despite
such gray areas in the knowledge of HIF-1,
controlofthistranscriptionfactordoesinfact
remain a high-priority target. Modulation of
the HIF-1 pathway promises to have signifi-
canteffectsoncancerandcardiactreatments,
potentiallyaffectingthelivesofmillionswho
are afflicted with such diseases.
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